-
2023-505311-20-00
5
Metastatic Non-Small Cell Lung Cancer
-
2024-514652-33-00
4
Relapsed Multiple Myeloma
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2022-503119-40-00
5
psoriatic arthritis (PsA)
-
2023-509392-17-00
5
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-513724-42-00
10
Medulloblastoma
-
2024-516864-27-00
4
Cardiac arrest
-
2024-517339-30-00
7
Advanced Solid Tumors
-
2024-517796-21-00
5
Prevention of recurrence after a first episode of Venous Thromboemboli
-
2024-517945-14-00
5
Inflammatory cardiomyopathy
-
2024-518420-80-00
5
Primary infection prophylaxis for secondary immunodeficiency (SID) in
-
2024-518617-25-00
4
newly diagnosed non-M3 FLT3-positive acute myeloid leukemia
-
2024-518912-37-01
4
Ewing Sarcoma
-
2024-520326-11-00
4
Acute Myeloid Leukemia (AML)
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-521651-22-00
4
hormone receptor positive, HER2-negative breast cancer
-
2025-521666-10-01
4
Mantle Cell Lymphoma
-
2025-521827-61-00
4
refractory/relapsed multiple myeloma
-
2025-522204-24-00
4
Drug-Related Side Effects and Adverse Reactions
-
2025-522376-82-00
5
allergic diseases (allergic rhinosinusitis, allergic asthma, allergy t
-
2025-522586-30-00
5
Psoriatic Arthritis
-
2025-523259-72-00
5
Hidradenitis Suppurativa (HS)
-
2025-523525-17-00
9
Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
-
2025-523551-54-00
6
PSORIATIC ARTHRITIS PATIENTS IN CLINICAL TRANSITION